Erratum: Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/enzalutamide versus anti-androgen receptor ASC-J9® lead to promotion versus suppression of prostate cancer metastasis (J. Biol. Chem. (2013) 288 (19359-19369) DOI: 10.1074/jbc.M113.477216)

Tzu Hua Lin, Soo Ok Lee, Yuanjie Niu, Defeng Xu, Liang Liang, Lei Li, Shauh Der Yeh, Naohiro Fujimoto, Shuyuan Yeh, Chawnshang Chang

Research output: Contribution to journalComment/debatepeer-review

Abstract

For Fig. 5E, in the last row stained for PSA, one of the images in the MDV group was mistakenly inserted as the ASC group with a vertical translation during article preparation. The correct images from the MDV group and ASC group are presented in the corrected figure. We sincerely apologize for the error, and we assure that the correction of the images will not alter the original results or conclusions.

Original languageEnglish
Pages (from-to)15796
Number of pages1
JournalJournal of Biological Chemistry
Volume295
Issue number46
DOIs
Publication statusPublished - Nov 13 2020

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Fingerprint

Dive into the research topics of 'Erratum: Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/enzalutamide versus anti-androgen receptor ASC-J9® lead to promotion versus suppression of prostate cancer metastasis (J. Biol. Chem. (2013) 288 (19359-19369) DOI: 10.1074/jbc.M113.477216)'. Together they form a unique fingerprint.

Cite this